Mesenchymal Stem Cell Targeting of Microscopic Tumors and Tumor Stroma Development Monitored by Noninvasive Imaging, Diagnosis, Prognosis

In vivo Positron Emission Tomography Imaging

Shih-Chieh Hung,1,3,6 Win-Ping Deng,2 Wen K. Yang,1,6 Ren-Shyan Liu,4,6 Chien-Chih Lee,2 Tzu-Chi Su,1,6 Rue-Jen Lin,1,6 Den-Mei Yang,1,6 Chi-Wei Chang,4 Wei-Hong Chen,2 Hon-Jian Wei,2 and Juri G. Gelovani7

Abstract

The aim of this study was to assess the efficacy human mesenchymal stem cells (hMSC) for targeting microscopic tumors and suicide gene or cytokine gene therapy. Immunodeficient mice were transplanted s.c. with human colon cancer cells of HT-29 Inv2 or CCS line, and 3 to 4 days later, i.v. with “tracer” hMSCs expressing herpes simplex virus type 1 thymidine kinase (HSV1-TK) and enhanced green fluorescent protein (EGFP) reporter genes. Subsequently, these tumors were examined for specificity and magnitude of HSV1-TK+, EGFP+ stem cell engraftment and proliferation in tumor stroma by in vivo positron emission tomography (PET) with 18F-labeled 9-(4-fluoro-3-hydroxymethylbutyl)-guanine ([18F]-FHBG). In vivo PET images of tumors growing for 4 weeks showed the presence of HSV1-TK+ tumor stroma with an average of 0.36 ± 0.24% ID/g [18F]-FHBG accumulation. In vivo imaging results were validated by in situ correlative histochemical, immunofluorescent, and cytometric analyses, which revealed EGFP expression in vWF+ and CD31+ endothelial cells of capillaries and larger blood vessels, in germinal layer of dermis and hair follicles proximal to the s.c. tumor site. These differentiated HSV1-TK+, GFP+ endothelial cells had limited proliferative capacity and a short life span of 2 weeks in tumor fragments transplanted into secondary hosts. We conclude that hMSCs can target microscopic tumors, subsequently proliferate and differentiate, and contribute to formation of a significant portion of tumor stroma. PET imaging should facilitate clinical translation of stem cell – based anticancer gene therapeutic approaches by providing the means for in vivo noninvasive whole-body monitoring of trafficking, tumor targeting, and proliferation of HSV1-tk-expressing “tracer” hMSCs in tumor stroma.

Tumor progression involves tumor cell proliferation and infiltration into surrounding tissue and induction of different adaptive pathophysiologic and pathomorphologic processes in tissues that become involved in the developing tumor stroma. Tissue remodeling and neovascularization are critical processes in tumor stroma development (1). Recent studies have identified three main mechanisms of tumor angiogenesis: (a) existing vessel co-option (2); (b) endothelial sprouting (3); and (c) systemic recruitment of bone marrow–derived progenitor cells, including endothelial and mesenchymal progenitor cells (4). Mesenchymal stem cells (MSC) derived from bone marrow (5) are capable of self-renewal and differentiation into various somatic lineages (6). The in vivo plasticity of MSC has been used in novel therapeutic approaches to repair structural damage of the bone (7), central nervous system (8), skin (9), blood vessels (10), and myocardium (11).

Previous studies have shown that the adoptively transferred MSCs can migrate and engraft into the stroma of established tumor lesions (12). This phenomenon forms the basis for the paradigm of the “Trojan Horse” approach, in which the adult stem cells are used as shuttle vectors for delivery of gene therapies into growing tumors. If proven clinically effective, such an approach may in the future provide the means for therapy of metastatic tumors. However, from the clinical...
perspective, it is critical to show that such an approach is not limited to radiologically and reliably detectable tumors but can also be used to target minimal residual disease and micrometastatic tumors. Therefore, in the current study, we aimed to investigate whether the MSCs after systemic i.v. administration will migrate and engraft into the microscopic tumor lesions during early stages of their development. Another question we explored was whether the proliferation of engrafted MSCs in the developing tumors can generate a significant fraction of tumor stroma, which could be subsequently eliminated with suicide gene therapy (e.g., HSV1-tk with ganciclovir), or provide the source for production of various antitumor cytokines, such as INF-β (12) or interleukin-2 (13).

To start addressing these questions, we used immortalized human MSCs (hMSC) that were lentivirally transduced with the herpes simplex virus type 1 thymidine kinase (HSV1-TK), and the Aequorea victoria enhanced green fluorescent protein (EGFP), under control of two separate promoters. As in the case of previously described TKGFP fusion reporter gene (14–17), the EGFP reporter gene facilitated the fluorescence-activated cell sorting–aided selection of transduced MSCs and their fluorescence microscopic visualization in vitro and in situ. The HSV1-TK reporter gene allowed for the repetitive molecular in vivo (micro-PET) for noninvasive peritumoral tissues (i.e., skin and hair follicles), stromal cells, as well as into different cellular components of differentiation into vascular endothelial and other tumor cells was described in our previous study (18) using an established from a primary tumor of a 63-year-old female with Duke C3 (BD Biosciences, San Jose, CA) invasion technique. The CCS line was immortalized by retroviral-mediated transduction of human papilloma virus E6/E7 genes, and maintained in DMEM containing 1 mg/mL glucose and 10% fetal bovine serum of a selected lot (Invitrogen, Carlsbad, CA; ref. 19). This immortalized hMSC line is >99% positive for CD29, CD44, CD90, CD105, SH2, and SH3 MSC characteristic markers. Human mesenchymal stem cells. The hMSC line was originally cultured from the bone marrow of a 61-year-old female donor, immortalized from retroviral-mediated transduction of human papilloma virus E6/E7 genes, and maintained in MEM containing 10 units/mL penicillin, 10 μg/mL streptomycin, 2 mmol/L glucose and 10% fetal bovine serum of a selected lot (Invitrogen, Carlsbad, CA; ref. 19). This immortalized hMSC line is >99% positive for CD29, CD44, CD90, CD105, SH2, and SH3 MSC characteristic markers. Lentiviral vector construction and transduction. The self-inactivating pT7-EFEGFP lentiviral vector backbone was originally developed and provided by Dr. Lung-Ji Chang (University of Florida, FL; ref. 20). The pT7-EFEGFP-TK vector, was constructed by inserting into the HSV1-TK gene driven by the HSV1-tk promoter into the Kpnl site of the pT7-EFEGFP vector that carries the EGFP reporter gene driven by the EF1α promoter. Procedures for DNA transfection of Te671 cells to produce packaged virus of pT7-EFEGFP-TK vector and for transduction of hMSC were previously described (21). Using the Te671 vector at a multiplicity of infection = 1, the EGFP expression was observed in close to 30% of hMSC. The transduced EGFP+ and HSV1-TK+ hMSCs were separated using FACS Vantage (BD Biosciences) and designated TG-hMSC “tracer cells.” Subsequently, the expression of HSV1-TK in TG-hMSCs was verified using in vitro radiotracer accumulation assay with [18F]-FHBG (16, 22) and by an in situ susceptibility test to ganciclovir (LD50 = 0.01 mmol/L) as previously described (23, 24). In contrast, nontransduced hMSCs and nontransduced colon cancer cells were insensitive to ganciclovir at 1 mmol/L and showed negligible uptake and retention of [18F]-FHBG in vitro. The proliferative rate of transduced and nontransduced hMSCs were similar.

Materials and Methods

Tumor cells. The invasive variant of HT-29 Inv2 colon carcinoma cells was described in our previous study (18) using an in vitro Matrigel (BD Biosciences, San Jose, CA) invasion technique. The CCS line was established from a primary tumor of a 63-year-old female with Duke C3, colon adenocarcinoma (Veteran Hospital, Taipei, Taiwan) and used within 30 in vitro passages. Both cell lines were grown in MEM containing 10 units/mL penicillin, 10 μg/mL streptomycin, 2 mmol/L glucose and 10% fetal bovine serum of a selected lot (Invitrogen, Carlsbad, CA; ref. 19). This immortalized hMSC line is >99% positive for CD29, CD44, CD90, CD105, SH2, and SH3 MSC characteristic markers. Human mesenchymal stem cells. The hMSC line was originally cultured from the bone marrow of a 61-year-old female donor, immortalized from retroviral-mediated transduction of human papilloma virus E6/E7 genes, and maintained in DMEM containing 1 mg/mL glucose and 10% fetal bovine serum of a selected lot (Invitrogen, Carlsbad, CA; ref. 19). This immortalized hMSC line is >99% positive for CD29, CD44, CD90, CD105, SH2, and SH3 MSC characteristic markers.
anti-mouse IgG antibody or PE-labeled anti-hvWF; and PE-labeled mouse monoclonal antibodies against human CD14 (PharMingen, San Diego, CA), CD31, CD90, CD105 (Serotec, Raleigh, NC), and smooth muscle actin (Chemicon, Temecula, CA). Isotype control antibodies were used in parallel to set negative gates. The cells were analyzed on a FACS Vantage cytofluorometer using Cell Quest software (BD Biotech, Research triangle Park, NC).

Results

**Micropositron emission tomography imaging of human mesenchymal stem cell targeted tumors.** In the first group of mice (n = 6), we assessed the ability of the MSCs coimplanted with tumor cells to proliferate inside the growing tumor lesions and contribute to the development of tumor stroma. In this group, two s.c. tumor xenografts were established by s.c. injection of a mixture of 1 × 10^6 HT-29 Inv2 cells and 5 × 10^5 tracer TG-hMSCs (HT-29 + TG-hMSC) into the right flank, and by s.c. injection of 1 × 10^6 HT-29 Inv2 cells alone (HT-29) into the left flank. The micro-PET imaging with [18F]-FHBG was done 4 weeks later and showed a profound uptake and retention of the radiotracer in HT-29 + TG-hMSC tumors (5.78 ± 4.79% ID/g), indicating persistent HSV1-TK expression by the tracer TG-hMSC-derived tumor stroma (Fig. 1A). In contrast, no [18F]-FHBG uptake and retention above body background was observed in the contralateral HT-29 tumors, which served as negative control.

In the second group of mice (n = 6), only one tumor xenograft per mouse was established by s.c. injection of 1 × 10^6 HT-29 Inv2 cells into the right flank. In this group, 5 × 10^5 tracer TG-hMSCs were administered through the tail vein 3 days after s.c. tumor injection. In this group, micro-PET imaging studies confirmed the ability of i.v. administered tracer TG-hMSCs to migrate to the sites of microscopic tumor.
lesions, engraft into these microscopic tumor lesions, and contribute to the development of a significantly portion of tumor stroma (Fig. 1B).

Similar results were observed in tumors produced from human colon adenocarcinoma cell line, CCS. Micro-PET images obtained at different days after s.c. injection of tumor cells showed the initial migration of i.v. administered tracer TG-hMSC to the sites of s.c. CCS tumor cell injection. Repetitive micro-PET imaging done at 15 and 27 days after tracer TG-hMSCs injection (18 and 30 days of tumor growth) showed exponentially increasing $^{[18F]}$-FHBG accumulation at the sites of s.c. CCS tumor cell injection (Fig. 1C and D), which is indicative of tracer TG-hMSC proliferation and significant contribution to growing tumor stroma development.

In the third group of mice ($n = 6$), we aimed to determine whether the tracer hMSC-derived tumor stromal cells retain stem cell properties (i.e., the capacity for self-renewal). To address this question, we obtained tumor tissue samples at the end of a 30-day imaging study conducted in the second group of animals and implanted s.c. aseptically minced tumor fragments of about 2 mm in diameter into the new nonobese diabetic/severe combined immunodeficient mouse recipients. Four weeks later, the recipient mice developed nonobese diabetic/severe combined immunodeficient mouse tumor fragments of about 2 mm in diameter into the new group of animals and implanted s.c. aseptically minced tumor tissue samples at the end of a 30-day imaging study conducted in the second group with i.v. administration of tracer TG-hMSCs, as well as in the second group with i.v. administration of tracer TG-hMSCs, the EGFP fluorescence and immunostaining were detectable mainly in cells forming the capillary-like structures (Fig. 2A, B, G, H, and I), in the cells within the inner layer of small arterioles (Fig. 2B and C), and in connective tissue cells showing exponentially increasing $^{[18F]}$-FHBG accumulation at the sites of s.c. CCS tumor cell injection (Fig. 1C and D), which is indicative of tracer TG-hMSC proliferation and significant contribution to growing tumor stroma development.

In situ validation of positron emission tomography imaging of tracer human mesenchymal stem cell proliferation in tumors. To validate micro-PET imaging results and to quantitate the magnitude of tracer TG-hMSCs proliferation in tumors in different study groups, fresh tumor tissue samples were gradually digested to obtain single-cell suspensions containing both the tumor and stromal cell fractions. The numbers of EGFP$^+$ cells were assessed by cytofluorometry and plotted over time (days of tumor growth in vivo; Fig. 4). Because only $5 \times 10^5$ tracer hMSCs were initially administered either by coin plantation or by i.v. injection, these data indicate that tracer TG-hMSCs had proliferated at least several times during the tumor stroma development. This was more evident when the cell numbers were fitted with an exponential function. The average doubling time of tracer coinjection of tumor cells and tracer TG-hMSCs, as well as in the second group with i.v. administration of tracer TG-hMSCs, the EGFP fluorescence and immunostaining were detectable mainly in cells forming the capillary-like structures (Fig. 2A, B, G, H, and I), in the cells within the inner layer of small arterioles (Fig. 2B and C), and in connective tissue cells showing exponentially increasing $^{[18F]}$-FHBG accumulation at the sites of s.c. CCS tumor cell injection (Fig. 1C and D), which is indicative of tracer TG-hMSC proliferation and significant contribution to growing tumor stroma development.

Microscopic analyses of tumor stroma and surrounding tissues. To validate the results of noninvasive in vivo micro-PET imaging and to further characterize the type of cellular elements in tumor stroma, we examined tumor tissue sections obtained in all groups of animals for the type of cells expressing EGFP. In the first group of mice with s.c. coinjection of tumor cells and tracer TG-hMSCs, as well as in the second group with i.v. administration of tracer TG-hMSCs, the EGFP fluorescence and immunostaining were detectable mainly in cells forming the capillary-like structures (Fig. 2A, B, G, H, and I), in the cells within the inner layer of small arterioles (Fig. 2B and C), and in connective tissue cells showing exponentially increasing $^{[18F]}$-FHBG accumulation at the sites of s.c. CCS tumor cell injection (Fig. 1C and D), which is indicative of tracer TG-hMSC proliferation and significant contribution to growing tumor stroma development.

In the third group of mice ($n = 6$), we aimed to determine whether the tracer hMSC-derived tumor stromal cells retain stem cell properties (i.e., the capacity for self-renewal). To address this question, we obtained tumor tissue samples at the end of a 30-day imaging study conducted in the second group of animals and implanted s.c. aseptically minced tumor fragments of about 2 mm in diameter into the new nonobese diabetic/severe combined immunodeficient mouse recipients. Four weeks later, the recipient mice developed nonobese diabetic/severe combined immunodeficient mouse tumor fragments of about 2 mm in diameter into the new group of animals and implanted s.c. aseptically minced tumor tissue samples at the end of a 30-day imaging study conducted in the second group with i.v. administration of tracer TG-hMSCs, as well as in the second group with i.v. administration of tracer TG-hMSCs, the EGFP fluorescence and immunostaining were detectable mainly in cells forming the capillary-like structures (Fig. 2A, B, G, H, and I), in the cells within the inner layer of small arterioles (Fig. 2B and C), and in connective tissue cells showing exponentially increasing $^{[18F]}$-FHBG accumulation at the sites of s.c. CCS tumor cell injection (Fig. 1C and D), which is indicative of tracer TG-hMSC proliferation and significant contribution to growing tumor stroma development.

In the third group of mice ($n = 6$), we aimed to determine whether the tracer hMSC-derived tumor stromal cells retain stem cell properties (i.e., the capacity for self-renewal). To address this question, we obtained tumor tissue samples at the end of a 30-day imaging study conducted in the second group of animals and implanted s.c. aseptically minced tumor fragments of about 2 mm in diameter into the new nonobese diabetic/severe combined immunodeficient mouse recipients. Four weeks later, the recipient mice developed nonobese diabetic/severe combined immunodeficient mouse tumor fragments of about 2 mm in diameter into the new group of animals and implanted s.c. aseptically minced tumor tissue samples at the end of a 30-day imaging study conducted in the second group with i.v. administration of tracer TG-hMSCs, as well as in the second group with i.v. administration of tracer TG-hMSCs, the EGFP fluorescence and immunostaining were detectable mainly in cells forming the capillary-like structures (Fig. 2A, B, G, H, and I), in the cells within the inner layer of small arterioles (Fig. 2B and C), and in connective tissue cells showing exponentially increasing $^{[18F]}$-FHBG accumulation at the sites of s.c. CCS tumor cell injection (Fig. 1C and D), which is indicative of tracer TG-hMSC proliferation and significant contribution to growing tumor stroma development.

In situ validation of positron emission tomography imaging of tracer human mesenchymal stem cell proliferation in tumors. To validate micro-PET imaging results and to quantitate the magnitude of tracer TG-hMSCs proliferation in tumors in different study groups, fresh tumor tissue samples were gradually digested to obtain single-cell suspensions containing both the tumor and stromal cell fractions. The numbers of EGFP$^+$ cells were assessed by cytofluorometry and plotted over time (days of tumor growth in vivo; Fig. 4). Because only $5 \times 10^5$ tracer hMSCs were initially administered either by coin plantation or by i.v. injection, these data indicate that tracer TG-hMSCs had proliferated at least several times during the tumor stroma development. This was more evident when the cell numbers were fitted with an exponential function. The average doubling time of tracer coinjection of tumor cells and tracer TG-hMSCs, as well as in the second group with i.v. administration of tracer TG-hMSCs, the EGFP fluorescence and immunostaining were detectable mainly in cells forming the capillary-like structures (Fig. 2A, B, G, H, and I), in the cells within the inner layer of small arterioles (Fig. 2B and C), and in connective tissue cells showing exponentially increasing $^{[18F]}$-FHBG accumulation at the sites of s.c. CCS tumor cell injection (Fig. 1C and D), which is indicative of tracer TG-hMSC proliferation and significant contribution to growing tumor stroma development.

Microscopic analyses of tumor stroma and surrounding tissues. To validate the results of noninvasive in vivo micro-PET imaging and to further characterize the type of cellular elements in tumor stroma, we examined tumor tissue sections obtained in all groups of animals for the type of cells expressing EGFP. In the first group of mice with s.c. coinjection of tumor cells and tracer TG-hMSCs, as well as in the second group with i.v. administration of tracer TG-hMSCs, the EGFP fluorescence and immunostaining were detectable mainly in cells forming the capillary-like structures (Fig. 2A, B, G, H, and I), in the cells within the inner layer of small arterioles (Fig. 2B and C), and in connective tissue cells showing exponentially increasing $^{[18F]}$-FHBG accumulation at the sites of s.c. CCS tumor cell injection (Fig. 1C and D), which is indicative of tracer TG-hMSC proliferation and significant contribution to growing tumor stroma development.
TG-hMSCs was 6.51 ± 0.36 days, as determined by dividing the ln(2) by the coefficients of exponential fits of data. The levels of micro-PET detectable [18F]-FHBG radioactivity concentration in CCS (s.c.) + TG-hMSCs (i.v.) tumors increased exponentially between days 17 and 30 and paralleled increasing numbers of EGFP+ cells in the growing tumors.

The sensitivity of micro-PET imaging of tracer TG-hMSCs could be calculated by dividing the number of recovered GFP+ cells from s.c. tumors by the corresponding tumor volume. For example, dividing 3.2 × 10^6 TG-hMSCs recovered from the day 18 CCS (s.c.) + TG-hMSCs (i.v.) tumors by their volume of about 120 mm^3, results in 2.6 × 10^4 cells/mm^3, that were reliably detectable by the micro-PET R4 after injection of 250 μCi [18F]-FHBG per animal. Because the micro-PET R4 can detect at least a 10- to 20-fold lower levels of radioactivity concentration, we can reliably extrapolate that the lower threshold of micro-PET imaging is close to 1,000 cells/mm^3.

**In situ quantitation of TG-hMSC progeny cells and cell surface markers.** In situ characterization of EGFP+ cells in HT-29 (s.c.) + TG-hMSC (i.v.) tumors involved PCR amplification of EGFP sequence (717 bp) using 1 μg of cellular DNA prepared from digestion-aided disaggregates of HT-29 (s.c.) + TG-hMSCs (i.v.) tumors and HT-29 (s.c.) tumors. In HT-29 (s.c.) + TG-hMSC (i.v.) tumors, the EGFP gene was barely detectable in readily dissociated, loose tumor cell fractions, but was abundant in the stromal cell fraction. In contrast, the EGFP gene was not detectable in tumors established from HT-29 cells only, without coadministration of TG-hMSCs. The TG-hMSC and HT-29 tumor cells were used as positive and negative controls, respectively (Fig. 5A).

Cytofluorometric analysis of HT-29 (s.c.) + TG-hMSC (i.v.) tumors showed that 11.5% of all cells were EGFP+ (Fig. 5B). We then used antibodies against various human cell surface markers to analyze the phenotype of the EGFP+ cells by immunocytofluorometry. An endothelial cell marker, vWF was found on about one third of the EGFP+ cells of HT29 (s.c.) + hMSC (i.v.) tumors (Fig. 5C). Elevated levels of CD31 endothelial marker (28) expression but low and undetectable levels of CD90 and CD105 were observed in stromal matrix-associated EGFP+ cells (Fig. 5C), although the CD90 and CD105 are known to be highly expressed in hMSCs (29).

None of the EGFP+ cells reacted with anti-human smooth muscle actin antibodies (data not shown). Thus, the targeted TG-hMSC had differentiated mainly into the endothelial but not the smooth muscle cell components in tumor angiogenesis, confirming prior immunohistochemical observations (Figs. 2 and 3).

**Apparent loss of self-renewal capacity of differentiated tracer TG-hMSC-derived stromal cells.** To determine if tumor-engrafted tracer hMSC-derived progeny stromal cells retain self-renewal capacity, we cultured in vitro the tumor and stromal cells obtained from digested tissue fragments of micro-PET positive CSS (s.c.) + hMSC (i.v.) tumors. After 5 days in culture, the EGFP+ fluorescent cells were visible within...
spheroid-like cellular clusters and flat colonies (Fig. 6A-D). The EGFP expression in these cultured cells was confirmed by immunocytofluorometry (Fig. 6E and F). However, these EGFP-expressing cells did not proliferate further under these culture conditions and were rapidly overgrown by the CCS colon cancer cells. These results are consistent with our observations with micro-PET imaging in experiments involving reimplantation of small tumor fragments into new recipient mice (the third study group; Fig. 1E).

Discussion

The aim of the current study was to assess whether the hMSCs can migrate and engraft into the microscopic tumors, subsequently proliferate and form a significant portion of developed tumor stroma. To achieve this aim, we used clinically applicable in vivo whole-body PET imaging with $^{18}$F-FHBG to noninvasively monitor the fate of genetically modified HSV1-TK- and EGFP-expressing “tracer” hMSCs (TG-hMSCs) upon their i.t. or i.v. administration. We use the term “tracer cells” in context of the potential future clinical scenario, in which the HSV1-TK-expressing hMSCs will be used to “trace” the coadministered therapeutic hMSCs genetically modified to express various anticancer cytokines (12, 13). Similar PET imaging approach was applied in several recent studies for noninvasively visualization of HSV1-TK-expressing stem cells after direct intramyocardial injection (30, 31) and for visualization of tumor targeting by the adoptively transferred tumor antigen-specific T cells (32, 33). Another potential clinical therapeutic protocol, which would be greatly facilitated by noninvasive imaging, would include repetitive (e.g., biweekly or monthly) administration of HSV1-TK-expressing autologous stem cells to patients following resection of a primary tumor, which has high likelihood of metastases that are radiologically not detectable at the time of resection. In case the local or distal metastases will be developing after resection of primary tumor, such repetitive administration of HSV1-TK-expressing stem cells would result in the development of HSV1-TK-expressing tumor stroma, which should be detectable with whole-body PET imaging. The HSV1-TK-expressing tumor stroma can be “eliminated” by treatment with ganciclovir, which should cause a significant regression of metastatic tumor lesions, the efficacy of which can be assessed by conventional

![Fig. 5. In situ characterization of EGFP+ cells in HT-29 (s.c.) + TG-hMSC (i.v.) tumors. A, agarose gel electrophoresis of PCR-amplified EGFP sequence (717 bp) done using 1 μg of cellular DNA prepared from loosely associated cell fraction (loose), stromal matrix associated fraction (stroma), and the residue (residue) of HT-29 (s.c.)/TG-hMSC (i.v.) tumor and HT-29 (s.c.) tumor, TG-hMSC, and HT-29 cells. B, cytofluorometric histograms comparing the stromal matrix cell fractions of HT-29 (s.c.) + TG-hMSC (i.v.) tumors (red) and HT-29 (s.c.) tumors (black), examined with anti-GFP specific antibody. EGFP+ cells in the gated area represented 11.5% of total cells. C, histograms showing the presence of human endothelial cell markers but absence of hMSC markers in EGFP+ cells obtained from the HT-29 (s.c.) + TG-hMSC (i.v.) tumor after 30 days of growth in vivo. Stromal matrix–associated cell fractions were double stained with FITC-labeled anti-GFP mouse monoclonal antibody, and with a PE-labeled anti-vWF, or anti-CD31, or anti-CD90, or anti-CD105 to assess the expression of these cell surface markers on EGFP+ cells (red). PE-labeled mouse isotype immunoglobulins were included in parallel to serve as the negative control (black).](http://www.aacrjournals.org/clinres/article-pdf/11/21/7754/19414581/CCL009580.pdf)

![Fig. 6. In vitro assessment of self-renewal capacity of differentiated tracer TG-hMSC-derived stromal cells. The morphology of digestion-aided disaggregated tissue fragments of micro-PET positive CSS (s.c.) + hMSC (i.v.) tumors after 5 days in culture as seen by dark field microscopy (A and C) and fluorescence microscopy of EGFP (B and D). The EGFP+ fluorescent cells are clearly visible within spheroid-like cellular clusters (A and B) and flat colonies (C and D). The EGFP expression in these cultured cells was confirmed by immunocytofluorometry using anti-eGFP antibody (F); the IgG isotype antibody was used for control (E).](http://www.aacrjournals.org/clinres/article-pdf/11/21/7754/19414581/CCL009580.pdf)
anatomic computed tomography, magnetic resonance, and $^{[18F]}$-FDG imaging. Thereafter, the cycle of therapy with HSV1-TK-expressing stem cells followed by whole-body PET imaging of HSV1-TK expression and ganciclovir therapy could be repeated.

As the initial step of our studies, we assessed whether the micro-PET imaging with $^{[18F]}$-FHBG is sensitive and specific enough for the detection of HSV1-TK-expressing tumor stroma in s.c. tumors that had been established by s.c. coinjection of colon HT29 carcinoma cells and tracer hMSCs in mice. The sensitivity of micro-PET imaging with $^{[18F]}$-FHBG depends on the level of HSV1-TK reporter gene expression per cell and the number of HSV1-TK$^+$ cells within the minimum resolution volume of $2 \times 2 \times 2$ mm for the Micro-PET R4 scanner (Concorde Microsystems). The calculated lower threshold of micro-PET R4 sensitivity in our in vivo imaging/in situ validation studies was close to 1,000 cells/mm$^3$, which is comparable with results reported previously, which estimated the lower threshold of Micro-PET R4 scanner sensitivity for imaging with $^{[18F]}$-FHBG sr39HSV1-TK-expressing cells as $10^8$ cells per 0.1 mL (or $10^7$ to $10^8$/mm$^3$ of tissue; refs. 31, 34).

Next, we did in vivo PET imaging and in situ analyses at 15 and 27 days after i.v. administration of HSV1-TK$^+$, GFP$^+$ tracer hMSCs in mice with microscopic s.c. CCS tumors. We showed that these cells engrafted into the microscopic tumors, subsequently proliferated with a calculated average doubling time of $6.51 \pm 0.36$ days, and contributed to the formation of a significant fraction of tumor stroma. We observed similar micro-PET imaging results with other human xenografts in nonobese diabetic/severe combined immunodeficient mice, including A431 epidermoid carcinoma, Ova-3 ovarian carcinoma, and Taiwan domestic patient CZF pancreatic carcinoma (data not shown). Tumor-targeting properties of stem cells have been previously reported in glioblastoma model (35); in studies of tumor angiogenesis by hematopoietic stem cells (4), stem cells were used as vehicles for gene therapy of human colon cancer xenografts (12). Cancer cells are known to produce various growth factors that stimulate angiogenesis (36). In response to these factors, endothelial precursors including bone marrow–derived endothelial progenitors (10) and hematopoietic stem cells (4) may be recruited into tumor neovascularization process. Whether some of these factors possess chemotactic and/or selective differentiation-inducing activities for MSC remains to be investigated. It remains to be determined whether the endogenous MSCs are mobilized by the microscopic tumors from the bone marrow and migrate to sites of microscopic tumors, and what percentage of tumor stroma develops from the engrafted MSCs.

Because the radiotracer used in the current study was $^{[18F]}$-FHBG, which produces in mice a substantial abdominal background due to predominantly hepatobiliary routes of elimination, we are unable to definitively answer this question. The use of another radiotracer, $^{[18F]}$-FEAU, in our future studies will potentially enable us to address this question, because $^{[18F]}$-FEAU is eliminated by renal clearance and produces almost no nonspecific background radioactivity levels in all tissues and organs (except for residual activity in the bladder; ref. 37). Nevertheless, the use of $^{[18F]}$-FHBG in combination with HSV1-sr39tk provides greater sensitivity to imaging compared with the wild-type HSV1-tk (38). However, it is conceivable that the majority of progenitor cells after i.v. injection into murine hosts that had not been bone marrow ablated do not engraft into bone marrow or other organs and do not proliferate to produce progeny tissues to the degree that is biologically significant; they remain dormant throughout the organism, or the majority of these cells undergo apoptosis, especially after xenotransplantation.

Our in vivo PET imaging observations were cross-validated by in situ and in vitro analyses. Specifically, the immunocyto-fluorometric analyses of tumors confirmed the presence of EGFP$^+$ progeny cells differentiated into endothelial cells of tumor capillaries and small blood vessels, hair follicle cells, and basal cells of dermis overlaying the s.c. tumor xenografts. The later observations may be explained, at least in part, by the capacity of stem cells to nonspecifically home into the sites of tissue damage and inflammation (39), which are often observed in the skin overlaying s.c. tumors.

Previously, it was shown that MSCs have the propensity to differentiate as osteogenic, chondrogenic, adipogenic, and neurogenic lineages in vitro (29, 40). It is not known if transdifferentiation from hMSC to epithelial cells at the tumor site could involve mechanisms, such as the recently reported in vitro fusion of hMSC with heat-shocked epithelial cells (9). These differentiated tracer hMSC-derived progeny cells had exhibited a limited capacity for self-renewal as evidenced from the retransplantation experiments we did. One possible explanation of these results is that HSV1-TK$^+$, GFP$^+$ tracer stem cells, which contributed to the development of the tumor stroma in the original host, subsequently diminished their proliferative capacity due to differentiation, which was also evident from our in vitro replating experiments. Another possible explanation is that by 4 weeks after transplantation into the new host the HSV1-TK$^+$, GFP$^+$ tracer stem cells from the transplanted tumor tissue became “diluted” within the newly developing tumor stroma and/or were substituted by the recipient host-derived stroma-forming cells. Similar results on limited renewal capacity and <2-week life span of tumor-derived endothelial cells in retransplanted tumors have been reported previously (41).

In conclusion, we believe that the current study is first to provide the direct evidence for microscopic tumor targeting by exogenously administered hMSCs. The i.v. administered HSV1-TK-expressing tracer hMSCs can be used for noninvasive monitoring of stem cell–based therapies using whole-body PET imaging with $^{[18F]}$-FHBG or other HSV1-TK-specific radiotracers $^{[18F]}$-FEAU and $^{[18F]}$-FAU (37, 42) or $^{[125I]}$-FAU (43, 44). It is also conceivable that PET imaging of i.v. administered HSV1-TK$^+$ tracer hMSCs can be exploited as a novel approach for noninvasive detection of otherwise radio logically nondetectable microscopic tumors and for monitoring the formation of HSV1-tk-expressing tumor stroma for ganciclovir therapy.

Acknowledgments

We thank Dr. Lung-Ji Chang (University of Florida) for supplying the original lentiviral vector system, Dr. H.E. Wang (National Yang-Min Medical University, Taipei) for the synthesis of FHBG precursor, and Dr. Otto O. Yang (University of California at Los Angeles) for editorial assistance.
References

Mesenchymal Stem Cell Targeting of Microscopic Tumors and Tumor Stroma Development Monitored by Noninvasive \textit{In vivo} Positron Emission Tomography Imaging

Shih-Chieh Hung, Win-Ping Deng, Wen K. Yang, et al.


Updated version  Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/11/21/7749

Cited articles  This article cites 42 articles, 21 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/11/21/7749.full.html#ref-list-1

Citing articles  This article has been cited by 21 HighWire-hosted articles. Access the articles at:
/content/11/21/7749.full.html#related-urls

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.